Cytokinetics director sells 4,032 shares at $75

Cytokinetics director Wendell Wierenga reported an exercise-and-sell transaction in company stock.

Rhea-AI Filing Summary

Cytokinetics director Wendell Wierenga reported an exercise-and-sell transaction in company stock. He exercised a non-qualified stock option for 4,032 shares of Common Stock at $12.40 per share and on the same date sold 4,032 shares in an open-market trade at $75.00 per share. After these transactions, he directly owns 32,637 shares of Cytokinetics Common Stock, and the option covering 4,032 shares has been fully exercised.

Insider Trade Summary 10b5-1

Exercise and Sale: 4,032 shares ($252K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider WIERENGA WENDELL

Role Director

Sold 4,032 shs ($302K)

Approx. gross sale proceeds $302K

Approx. exercise cost $50K

Approx. pre-tax spread $252K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	4,032	$0.00	$0.00
Exercise	Common Stock	4,032	$12.40	$50K
Sale	Common Stock	4,032	$75.00	$302K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 32,637 shares (Direct)

Footnotes (1)

1. F1. This option shall vest and become exercisable as to 4,032 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018.

Key Figures

Shares sold: 4,032 shares Sale price: $75.00 per share Option exercise shares: 4,032 shares +3 more

6 metrics

Shares sold 4,032 shares Common Stock sold in open-market transaction

Sale price $75.00 per share Price for 4,032 shares of Common Stock

Option exercise shares 4,032 shares Non-Qualified Stock Option exercised into Common Stock

Option exercise price $12.40 per share Exercise price of Non-Qualified Stock Option

Shares owned after transaction 32,637 shares Direct Common Stock holdings following transactions

Option expiration January 3, 2027 Original expiration date of exercised option grant

Key Terms

Non-Qualified Stock Option (Right to Buy), open-market sale, derivative exercise/conversion, derivative security, +1 more

5 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

total shares following transaction financial

""total_shares_following_transaction": "32637.0000""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cytokinetics (CYTK) director Wendell Wierenga report on this Form 4?

Wendell Wierenga reported an exercise-and-sell transaction involving Cytokinetics Common Stock. He exercised a non-qualified stock option for 4,032 shares at $12.40 per share and sold 4,032 shares in an open-market trade at $75.00 per share on the same date.

How many Cytokinetics (CYTK) shares did Wendell Wierenga sell and at what price?

He sold 4,032 shares of Cytokinetics Common Stock in an open-market transaction at $75.00 per share. This sale was paired with an option exercise for the same number of shares, reflecting a typical exercise-and-sell pattern for previously granted equity compensation.

What stock option did Wendell Wierenga exercise in this Cytokinetics (CYTK) filing?

He exercised a Non-Qualified Stock Option covering 4,032 shares of Cytokinetics Common Stock at an exercise price of $12.40 per share. The option, which fully vested by January 3, 2018, is now fully exercised with zero derivative shares remaining after this transaction.

How many Cytokinetics (CYTK) shares does Wendell Wierenga own after these transactions?

Following the reported transactions, Wendell Wierenga directly holds 32,637 shares of Cytokinetics Common Stock. This figure reflects his position after exercising options for 4,032 shares and selling 4,032 shares on the same date, as disclosed in the Form 4 data.

Is this Cytokinetics (CYTK) Form 4 transaction an example of an exercise-and-sell pattern?

Yes. Wierenga exercised a Non-Qualified Stock Option for 4,032 shares at $12.40 per share and sold 4,032 shares at $75.00 per share on the same date. This combination is a classic exercise-and-sell pattern for monetizing previously granted stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/05/2026 - 04:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WIERENGA WENDELL

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		M		4,032	A	$12.4	36,669	D
Common Stock	05/05/2026		S		4,032	D	$75	32,637	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$12.4	05/05/2026		M			4,032	02/03/2017(1)	01/03/2027	Common Stock	4,032	$0	0	D

Explanation of Responses:

1. This option shall vest and become exercisable as to 4,032 shares divided into equal monthly installments such that the option shall be 100% vested on January 3, 2018.

	/s/ John O. Faurescu, attorney-in-fact for Dr. Wierenga	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)